Manage settings
MENU
About this site
In het Nederlands
Home
Researchers
Projects
Organisations
Publications
Infrastructure
Contact
Research Explorer
Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.
Researcher
Asif Hameed Khan
Profile
Projects
Publications
Activities
Awards & Distinctions
92
Results
2024
Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis
Claus Bachert
Philippe Gevaert
Brian Lipworth
Syed Shahzad Mustafa
Andrew P. Lane
Joaquim Mullol
Paul Rowe
Yamo Deniz
Siddhesh Kamat
Asif Hameed Khan
et al.
A1
Journal Article
in
ALLERGY
2024
2022
AROMA : real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps
Shahid Siddiqui
Claus Bachert
Adam M. Chaker
Joseph K. Han
Peter Hellings
Anju T. Peters
Enrico Heffler
Siddhesh Kamat
Haixin Zhang
Scott Nash
et al.
A1
Journal Article
in
ERJ OPEN RESEARCH
2022
Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD) : measurement properties of novel patient-reported symptom measures
Adam Gater
Linda Nelsen
Cheryl D Coon
Sonya Eremenco
Sean O’Quinn
Asif Hameed Khan
Laurent Eckert
Hannah Staunton
Nicola Bonner
Rebecca Hall
et al.
A1
Journal Article
in
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
2022
Chronic rhinosinusitis : natural history, impact on health-related quality of life, and patient perspectives
Asif Hameed Khan
Claus Bachert
Thibaut Van Zele
Dissertation
2022
Development of Sinonasal Outcome Test (SNOT-22) domains in chronic rhinosinusitis with nasal polyps
Asif Hameed Khan
Matthew Reaney
Isabelle Guillemin
Lauren Nelson
Shanshan Qin
Siddhesh Kamat
Leda Mannent
Nikhil Amin
Diane Whalley
Claire Hopkins
A1
Journal Article
in
LARYNGOSCOPE
2022
Dupilumab achieves durable reduction in severity of symptoms rated most important by patients with chronic rhinosinusitis with nasal polyps
Claire Hopkins
Stella Lee
Wytske Fokkens
Eugene Chang
Jérôme Msihid
Asif Hameed Khan
Urvi Mujumdar
Siddhesh Kamat
Scott Nash
Shahid Siddiqui
et al.
C3
Conference
2022
Dupilumab demonstrates rapid onset of response across three type 2 inflammatory diseases
G Walter Canonica
Arnaud Bourdin
Anju T Peters
Martin Desrosiers
Claus Bachert
Stephan Weidinger
Eric L Simpson
Nadia Daizadeh
Zhen Chen
Siddesh Kamat
et al.
A1
Journal Article
in
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
2022
Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps : association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS‐24 and SINUS‐52 trials
Claus Bachert
Jonathan Corren
Stella E. Lee
Haixin Zhang
Sivan Harel
Danen Cunoosamy
Asif Hameed Khan
Juby A. Jacob‐Nara
Shahid Siddiqui
Scott Nash
et al.
Editorial material
2022
Dupilumab improves asthma control, and allergic rhinitis-related health-related quality of life in children with uncontrolled persistent asthma with comorbid allergic rhinitis
Alessandro Fiocchi
Wanda Phipatanakul
Sandy Durrani
Jeremy Cole
Dongfang Liu
Jérôme Msihid
David Lederer
Megan Hardin
Yi Zhang
Asif Hameed Khan
C3
Conference
2022
Dupilumab improves health related quality of life : results from the phase 3 SINUS studies
Stella E Lee
Claire Hopkins
Joaquim Mullol
Jérôme Msihid
Isabelle Guillemin
Nikhil Amin
Leda P Mannent
Yongtao Li
Shahid Siddiqui
Chien Chia Chuang
et al.
A1
Journal Article
in
ALLERGY
2022
Dupilumab improves health-related quality of life : results from the phase 3 SINUS studies
Stella E Lee
Claire Hopkins
Joaquim Mullol
Jérôme Msihid
Isabelle Guillemin
Nikhil Amin
Leda P Mannent
Yongtao Li
Shahid Siddiqui
Chien-Chia Chuang
et al.
A1
Journal Article
in
ALLERGY
2022
Dupilumab improves objective, subjective, and health-related quality of life outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP), regardless of BMI≥ 30 kg/m2 or weight≥ 90 kg : post-hoc analysis of the SINUS-24 and SINUS-52 studies
Seong Cho
Bruce Tan
Noam Cohen
Jody Tversky
Elina Toskala
Scott Nash
Haixing Zhang
Shahid Siddiqui
Asif Hameed Khan
Juby Jacob-Nara
et al.
C3
Conference
2022
Dupilumab leads to reduction of anosmia in patients with severe chronic rhinosinusitis with nasal polyps
Andrew Lane
Joaquim Mullol
Claire Hopkins
Wytske Fokkens
Stella Lee
Asif Hameed Khan
Jérôme Msihid
Scott Nash
Shahid Siddiqui
Urvi Mujumdar
et al.
C3
Conference
2022
Dupilumab reduces asthma disease burden and recurrent SCS use in patients with CRSwNP and coexisting asthma
Mark Gurnell
Andrew Menzies-Gow
Claus Bachert
Njira Lugogo
Seong Cho
Shahid Siddiqui
Scott Nash
Haixin Zhang
Asif Hameed Khan
Juby Jacob Nara
et al.
C3
Conference
2022
Evaluating treatment responses of dupilumab versus omalizumab in type 2 patients : the EVEREST trial
Lucia de Prado Gomez
Asif Hameed Khan
Anju Peters
Claus Bachert
Martin Wagenmann
Enrico Heffler
Claire Hopkins
Peter Hellings
Mei Zhang
Jun Xing
et al.
C3
Conference
2022
Impact of dupilumab on SNOT-22 sleep and function scores in CRSwNP
William W. Busse
Andrew Wellman
Zuzana Diamant
Noam A. Cohen
Adam M. Chaker
Claus Bachert
Shahid Siddiqui
Haixin Zhang
Scott Nash
Asif Hameed Khan
et al.
A1
Journal Article
in
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
2022
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE) : an open-label extension study
Michael E Wechsler
Linda B Ford
Jorge F Maspero
Ian D Pavord
Alberto Papi
Arnaud Bourdin
Henrik Watz
Mario Castro
Natalia M Nenasheva
Yuji Tohda
et al.
A1
Journal Article
in
LANCET RESPIRATORY MEDICINE
2022
Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps
Joaquim Mullol
Claus Bachert
Nikhil Amin
Martin Desrosiers
Peter W Hellings
Joseph K Han
Roger Jankowski
Jan Vodicka
Philippe Gevaert
Nadia Daizadeh
et al.
A1
Journal Article
in
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
2022
Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma
Eric D Bateman
Asif Hameed Khan
Yingxin Xu
Patricia Guyot
Jingdong Chao
Siddhesh Kamat
Paul Rowe
Heather Burnett
Jerome Msihid
David Weinreich
A1
Journal Article
in
RESPIRATORY MEDICINE
2022
Rapid and continuing improvements in nasal symptoms with dupilumab in patients with severe CRSwNP
Claus Bachert
Asif Hameed Khan
Claire Hopkins
Michael S. Blaiss
Zachary M. Soler
Scott Nash
Shahid Siddiqui
Amy Praestgaard
Yamo Deniz
Paul J. Rowe
et al.
A1
Journal Article
in
JOURNAL OF ASTHMA AND ALLERGY
2022
Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
Peter Hellings
Anju T Peters
Adam M Chaker
Enrico Heffler
Haixin Zhang
Amy Praestgaard
Scott Nash
Asif Hameed Khan
Shahid Siddiqui
Juby A Jacob-Nara
et al.
Editorial material
2022
Response to comment on : Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma (Respir. Med. 2020)
Eric D Bateman
Asif Hameed Khan
Yingxin Xu
Patricia Guyot
Jingdong Chao
Siddhesh Kamat
Heather Burnett
Jerome Msihid
David M Weinreich
Ian Pavord
A1
Journal Article
in
RESPIRATORY MEDICINE
2022
Response to the correspondence : 'Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma'
Eric D Bateman
Asif Hameed Khan
Yingxin Xu
Patricia Guyot
Paul Rowe
Heather Burnett
Jerome Msihid
David Weinreich
Ian Pavord
A1
Journal Article
in
RESPIRATORY MEDICINE
2022
Symptom free days in patients with severe chronic rhinosinusitis with nasal polyps treated with dupilumab
Claus Bachert
Claire Hopkins
Joseph Han
Wytske Fokkens
Leda Mannent
Asif Hameed Khan
Jerome Msihid
Urvi Mujumdar
Siddhesh Kamat
Scott Nash
et al.
C3
Conference
2022
2021
Association between dupilumab effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24 and SINUS-52 trials
Claus Bachert
J Corren
SE Lee
H Zhang
S Harel
D Cunoosamy
Asif Hameed Khan
JA Jacob-Nara
S Siddiqui
S Nash
C3
Conference
2021
Dupilumab efficacy and safety in children with uncontrolled, moderate-to-severe asthma : the phase 3 VOYAGE study
LB Bacharier
JF Maspero
CH Katelaris
AG Fiocchi
R Gagnon
I de Mir
N Jain
LD Sher
X Mao
D. Liu
et al.
C3
Conference
2021
Dupilumab efficacy vs standard of care in patients with uncontrolled, persistent asthma–a meta analysis
ID Pavord
Asif Hameed Khan
B Neupane
P Guyot
S Kamat
J Chao
P Rowe
J Msihid
Y Xu
C3
Conference
2021
Dupilumab improves CRSWNP/asthma outcomes in patients with CRSWNP and comorbid asthma irrespective of asthma characteristics
W Busse
I Pavord
S Siddiqui
Asif Hameed Khan
A Praestgaard
S Nash
J Jacob-Nara
P Rowe
Y Deniz
C3
Conference
2021
Dupilumab improves asthma control and quality of life in children with uncontrolled persistent asthma
Alessandro Fiocchi
Wanda Phipatanakul
Sandy R Durrani
Jeremy Cole
Xuezhou Mao
Jérôme Msihid
David J Lederer
Megan Hardin
Yi Zhang
Asif Hameed Khan
C3
Conference
2021
Dupilumab in children with uncontrolled moderate-to-severe asthma
Leonard B Bacharier
Jorge F Maspero
Constance H Katelaris
Alessandro G Fiocchi
Remi Gagnon
Ines de Mir
Neal Jain
Lawrence D Sher
Xuezhou Mao
D. Liu
et al.
A1
Journal Article
in
NEW ENGLAND JOURNAL OF MEDICINE
2021
Dupilumab leads to clinical asthma remission indicative of comprehensive improvement in patients with asthma
I Pavord
W Busse
E Israel
S Szefler
Z Chen
Asif Hameed Khan
D Lederer
Y Zhang
C3
Conference
2021
Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps : results from the SINUS-24 and SINUS-52 phase 3 trials
Philippe Gevaert
SE Lee
R Settipane
M Wagenmann
J Msihid
S Siddiqui
S Nash
JA Jacob-Nara
Asif Hameed Khan
S Kamat
et al.
C3
Conference
2021
Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP
M. Desrosiers
L.P. Mannent
N. Amin
G.W. Canonica
Peter Hellings
Philippe Gevaert
J. Mullol
S.E. Lee
S. Fujieda
J.K. Han
et al.
A1
Journal Article
in
RHINOLOGY
2021
Dupilumab shows sustained efficacy and improvements in asthma control and health-related quality of life in patients with moderate-to-severe asthma : liberty asthma traverse
M Wechsler
LB Ford
JF Maspero
ID Pavord
D Langton
C Domingo
A Papi
A Bourdin
H Watz
X. Mao
et al.
C3
Conference
2021
Dupilumab treatment leads to clinical asthma remission in patients with uncontrolled moderate-to-severe asthma with type 2 inflafmmation
Ian Pavord
William Busse
Elliot Israel
Stanley Szefler
Zhen Chen
Nadia Daizadeh
David Lederer
Leda Mannent
Nikhil Amin
Elizabeth Laws
et al.
C3
Conference
2021
Effect of dupilumab on improving physical activity in patients with severe asthma
Lawrence Sher
Santiago Quirce
Giovanni Passalacqua
Camille Taillé
Lauren Cohn
Nadia Daizadeh
Nami Pandit-Abid
Benjamin Ortiz
Asif Hameed Khan
Yi Zhang
C3
Conference
2021
Effect of dupilumab on patient-reported sleep outcomes in patients with severe asthma
Lawrence Sher
Giovanni Passalacqua
Camille Taillé
Lauren Cohn
Santiago Quirce
Nadia Daizadeh
Nami Pandit-Abid
Benjamin Ortiz
Asif Hameed Khan
Yi Zhang
C3
Conference
2021
Efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps and allergic rhinitis
A Peters
M Wagenmann
JA Bernstein
H Zhang
Asif Hameed Khan
S Nash
JA Jacob-Nara
S Siddiqui
C3
Conference
2021
Health-related quality of life impairment among patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 trial
Jorge Maspero
Carl Philpott
Peter Hellings
Claire Hopkins
Martin Wagenmann
Shahid Siddiqui
Juby Jacob-Nara
Jerome Msihid
Chien-Chia Chuang
Siddhesh Kamat
et al.
C3
Conference
2021
Impact of dupilumab on sleep/function scores in patients with chronic rhinosinusitis with nasal polyps
W Busse
A Wellman
Claus Bachert
S Siddiqui
H Zhang
Asif Hameed Khan
J Jacob-Nara
P Rowe
Y Deniz
C3
Conference
2021
Improvement in patient-reported ’taste’ and association with smell in dupilumab-treated severe chronic rhinosinusitis with nasal polyps patients from the SINUS-24 and SINUS-52 trials
AT Peters
ZM Soler
Kern Rc
E Heffler
JF Maspero
L Crampette
S Fujieda
AP Lane
H Zhang
S. Nash
et al.
C3
Conference
2021
Liberty asthma traverse dupilumab shows sustained efficacy and improvements in asthma control and health-related quality of life (HRQOL) in patients with moderate-to-severe asthma
M Wechsler
LB Ford
JF Maspero
ID Pavord
D Langton
C Domingo
A Papi
A Bourdin
H Watz
X. Mao
et al.
C3
Conference
2021
Long-term efficacy of dupilumab in patients with moderate-to-severe asthma in the liberty asthma traverse open-label extension study : improvements in asthma control and health-related quality of life
ID Pavord
ME Wechsler
LB Ford
JF Maspero
D Langton
C Domingo
A Papi
A Bourdin
H Watz
X. Mao
et al.
C3
Conference
2021
Rapid and sustained effects of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps : analysis of the SINUS-24 and SINUS-52 phase 3 trails
Peter Hellings
A Peters
AM Chaker
E Heffler
H Zhang
N Daizadeh
S Nash
Asif Hameed Khan
S Siddiqui
JA Jacob-Nara
C3
Conference
2021
Reducing fungal exposure critical for treating rhinosinusitis with or without polyps [response to letter]
Claus Bachert
Neil Bhattacharyya
Martin Desrosiers
Asif Hameed Khan
A1
Journal Article
in
JOURNAL OF ASTHMA AND ALLERGY
2021
SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials
Joaquim Mullol
Giorgio Walter Canonica
Martin Wagenmann
Andre Coste
Peter Hellings
Scott Nash
Siddhesh Kamat
Urvi Mujumdar
Jérôme Msihid
Asif Hameed Khan
et al.
C3
Conference
2021
2020
A post hoc analysis of dupilumab efficacy in asthma patients with comorbid allergic rhinitis and chronic rhinosinusitis/nasal polyps from the LIBERTY ASTHMA QUEST study
JF Maspero
P Kuna
LB Ford
A Valero Santiago
N Daizadeh
P Rowe
Y Deniz
S Kamat
Asif Hameed Khan
N Pandit-Abid
et al.
C3
Conference
2020
Association between asthma severity, quality of life, and productivity in France, Germany, Italy, Spain, and the United Kingdom
Asif Hameed Khan
Nikoletta Sternbach
Siddhesh Kamat
Kathy Annunziata
Dena Jaffe
Imène Gouia
C3
Conference
2020
Availability of fractional exhaled nitric oxide (FeNO) and eosinophil (EOS) count data among patients with severe asthma in five European countries
Siddhesh Kamat
Imène Gouia
Jingdong Chao
Mark Small
Asif Hameed Khan
James Siddall
C3
Conference
2020
Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma
Jonathan Corren
Mario Castro
Thomas O’Riordan
Nicola A Hanania
Ian D Pavord
Santiago Quirce
Bradley E Chipps
Sally E Wenzel
Karthinathan Thangavelu
Megan S Rice
et al.
A1
Journal Article
in
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
2020
Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis
Jorge F Maspero
Constance H Katelaris
William W Busse
Mario Castro
Jonathan Corren
Bradley E Chipps
Anju T Peters
Ian D Pavord
Linda B Ford
Lawrence Sher
et al.
A1
Journal Article
in
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
2020
Dupilumab improves asthma control as assessed by total and individual item scores of the 6-item asthma control questionnaire in patients with severe chronic rhinosinusitis with nasal polyps and comorbid asthma : pooled results from the SINUS-24 and SINUS-52 phase 3 studies
Claus Bachert
JK Han
M Desrosiers
PW Hellings
X Mao
M Zhang
N Amin
LP Mannent
S Kamat
Asif Hameed Khan
C3
Conference
2020
Dupilumab improves patient-reported breathing in oral corticosteroid-dependent severe asthma
Lawrence Sher
Robert Wolfe
Santiago Quirce
Lauren Cohn
Giovanni Passalacqua
Pierluigi Paggiaro
Camille Taillé
Nadia Daizadeh
Benjamin Ortiz
Nami Pandit-Abid
et al.
C3
Conference
2020
Dupilumab rapidly improves sense of smell in patients with severe chronic rhinosinusitis with nasal polyps : pooled results from the SINUS-24 and SINUS-52 phase 3 studies
J. Mullol
Claus Bachert
M. Desrosiers
J. K. Han
R. Jankowski
N. Daizadeh
N. Amin
L. P. Mannent
Asif Hameed Khan
S. Kamat
C3
Conference
2020
Dupilumab reduced severe exacerbations and improved lung function in patients with uncontrolled, moderate-to-severe asthma with an eosinophilic phenotype across baseline IgE levels : LIBERTY ASTHMA QUEST study
WW Carr
J Corren
TB Casale
N Daizadeh
Asif Hameed Khan
S Kamat
Y Deniz
P Rowe
C3
Conference
2020
Dupilumab reduces severe outpatient asthma exacerbations, cumulative dose, and total number of days of systemic corticosteroid use among patients with moderate-to-severe type-2 asthma
Giorgio Walter Canonica
Robert Zeiger
Mario Castro
Jerome Msihid
Benjamin Ortiz
Nami Pandit-Abid
Siddhesh Kamat
Asif Hameed Khan
C3
Conference
2020
Effect of Dupilumab on patient-reported breathing and rescue medication use
Jonathan Corren
Mario Castro
Jorge F Maspero
William W Busse
Antonio Valero Santiago
Piotr Kuna
Nadia Daizadeh
Nami Pandit-Abid
Benjamin Ortiz
Asif Hameed Khan
et al.
C3
Conference
2020
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis
William W Busse
Jorge F Maspero
Yufang Lu
Jonathan Corren
Nicola A Hanania
Bradley E Chipps
Constance H Katelaris
J Mark FitzGerald
Santiago Quirce
Linda B Ford
et al.
A1
Journal Article
in
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
2020
Meta-analyses of dupilumab versus standard of care in patients with uncontrolled, persistent asthma
ID Pavord
Asif Hameed Khan
B Neupane
P Guyot
S Kamat
J Chao
P Rowe
J Msihid
Y Xu
C3
Conference
2020
Prevalence of asthma in France, Germany, Italy, Spain, and the United Kingdom, based on the 2018 European National Health and Wellness survey
Asif Hameed Khan
Nikoletta Sternbach
Siddhesh Kamat
Kathy Annunziata
Dena Jaffe
Imène Gouia
C3
Conference
2020
Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis
Asif Hameed Khan
Imène Gouia
Siddhesh Kamat
Benjamin Ortiz
Robert Johnson
James Siddall
Mark Small
C3
Conference
2020
2019
Baseline characteristics of patients with chronic rhinosinusitis with nasal polyps (with and without asthma) enrolled in SINUS-52 : a randomized, double-blind, phase 3 study of dupilumab
Claus Bachert
M Desrosiers
J Mullol
JF Maspero
M Wagenmann
I Niemann
Asif Hameed Khan
S Kamat
N Amin
LP Mannent
C3
Conference
2019
Baseline-Charakteristika von Patienten mit chronischer Rhinosinusitis mit nasalen Polypen (mit und ohne Asthma) in SINUS-52 : einer randomisierten, doppel-blinden, Phase-3-Studie von Dupilumab
Claus Bachert
M Desrosiers
J Mullol
JF Maspero
M Wagenmann
I Niemann
Asif Hameed Khan
S Kamat
N Amin
LP Mannent
C3
Conference
2019
Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps
Neil Bhattacharyya
Sara Villeneuve
Vijay N Joish
Caroline Amand
Leda Mannent
Nikhil Amin
Paul Rowe
Jaman Maroni
Laurent Eckert
Tony Yang
et al.
A1
Journal Article
in
LARYNGOSCOPE
2019
Dupilumab consistently improves rhinoconjunctivitis-specific health-related quality of life in patients with uncontrolled, moderate-to-severe asthma and comorbid allergic rhinitis : results from the phase 3 LIBERTY ASTHMA QUEST study
Jean Bousquet
Jorge F Maspero
Bradley E Chipps
Jonathan Corren
J Mark FitzGerald
Zhen Chen
Yufang Lu
Paul Rowe
Heribert Staudinger
Marcella Ruddy
et al.
C3
Conference
2019
Dupilumab improved asthma control across baseline immunoglobulin E levels : liberty asthma quest study
W Carr
J Corren
M Rice
Y Deniz
P Rowe
A Teper
Asif Hameed Khan
S Kamat
C3
Conference
2019
Dupilumab improved asthma control and health-related quality of life in patients with oral-corticosteroid-dependent severe asthma in the phase 3 LIBERTY ASTHMA VENTURE study
LB Ford
KF Rabe
RN Wolfe
S Quirce
MS Rice
P Rowe
Y Lu
S Kamat
N Amin
N.M.H. Graham
et al.
C3
Conference
2019
Dupilumab improved asthma control in patients with uncontrolled, moderate-to-severe asthma, regardless of exacerbations in the previous year
Stephanie Korn
Jonathan Corren
Mario Castro
J Maspero
Zhen Chen
Ina Niemann
Siddhesh Kamat
Nikhil Amin
Ariel Teper
Asif Hameed Khan
C3
Conference
2019
Dupilumab improved morning and evening daily asthma symptoms in patients with oral-corticosteroid-dependent severe asthma in the phase 3 LIBERTY ASTHMA VENTURE study
L Sher
KF Rabe
RN Wolfe
S Quirce
MS Rice
P Rowe
Y Lu
S Kamat
N. Amin
NMH Graham
et al.
C3
Conference
2019
Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history
Jonathan Corren
Mario Castro
Linda B Ford
Jonathan A Bernstein
Shyamalie Jayawardena
Jaman Maroni
Paul Rowe
Nikhil Amin
Gianluca Pirozzi
Neil M.H. Graham
et al.
A1
Journal Article
in
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
2019
Dupilumab improves health-related quality of life in patients with oral corticosteroid-dependent, severe asthma with comorbid chronic rhinosinusitis with and without nasal polyps
JF Maspero
KF Rabe
M Castro
MS Rice
P Rowe
Y Deniz
N Amin
S Kamat
A Teper
Asif Hameed Khan
C3
Conference
2019
Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD
Tanya M Laidlaw
Joaquim Mullol
Chunpeng Fan
Donghui Zhang
Nikhil Amin
Asif Hameed Khan
Jingdong Chao
Leda P Mannent
A1
Journal Article
in
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
2019
The GALEN rhinosinusitis cohort : chronic rhinosinusitis with nasal polyps affects health-related quality of life
Asif Hameed Khan
Thi Minh Thao Huynh
Griet Vandeplas
Vijay N Joish
Leda P Mannent
Peter Tomassen
Thibaut Van Zele
Lars-Olaf Cardell
Julia Arebro
Heidi Olze
et al.
A1
Journal Article
in
RHINOLOGY
2019
The Global Allergy and Asthma European Network (GALEN) rhinosinusitis cohort : a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps
Asif Hameed Khan
Griet Vandeplas
Thi Minh Thao Huynh
Vijay N. Joish
Leda Mannent
Peter Tomassen
Thibaut Van Zele
Lars-Olaf Cardell
Julia Arebro
Heidi Olze
et al.
A1
Journal Article
in
RHINOLOGY
2019
2018
A randomized, controlled phase 3 study, LIBERTY ASTHMA QUEST, evaluating the efficacy and safety of dupilumab in uncontrolled moderate-to-severe asthma
M Castro
J Corren
ID Pavord
JF Maspero
SE Wenzel
KF Rabe
WW Busse
LB Ford
L Sher
J. FitzGerald
et al.
C3
Conference
2018
Dupilumab demonstrates rapid and sustained improvements in daily asthma-related symptoms in patients with uncontrolled, moderate-to-severe asthma : data from the Liberty Asthma Quest study
Jo Douglass
David Langton
Jonathan Corren
Mario Castro
Sophie Guillonneau
Jingdong Chao
Nikhil Amin
Neil MH Graham
Ariel Teper
Asif Hameed Khan
C3
Conference
2018
Dupilumab improves ACQ-5 items in CRSwNP patients with comorbid asthma
Peter Hellings
Claus Bachert
J Mullol
D Hamilos
R Naclerio
L Mannent
N Amin
C Taniou
G Pirozzi
N. Graham
et al.
C3
Conference
2018
Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polypsosis (CRS/NP) in LIBERTY ASTHMA QUEST
William Busse
Jorge F Maspero
Contance H Katelaris
Dinesh Saralaya
Sophie Guillonneau
Bingzhi Zhang
Christine Taniou
Heribert Staudinger
Jingdong Chao
Nikhil Amin
et al.
C3
Conference
2018
Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST
Jonathan Corren
Mario Castro
Jorge F Maspero
Antonio L Valero Santiago
Piotr Kuna
Sophie Guillonneau
Qunming Dong
Christine Taniou
Heribert Staudinger
Jingdong Chao
et al.
C3
Conference
2018
Dupilumab improves health related quality of life in uncontrolled, moderate-to-severe asthma patients with comorbid allergic rhinitis from the phase 3 LIBERTY ASTHMA QUEST study
J Maspero
WW Busse
CH Katelaris
A Yanez
S Guillonneau
Z Chen
H Staudinger
J Chao
N Amin
G. Pirozzi
et al.
C3
Conference
2018
Dupilumab improves mental health measures in patients with chronic rhinosinusitis and nasal polyposis (CRSwNP)
Claus Bachert
Robert Naclerio
Peter Hellings
Sophie Guillonneau
Christine Taniou
Jaman Maroni
Paul Rowe
Leda Mannent
Nikhil Amin
Siddesh Kamat
et al.
C3
Conference
2018
Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and NSAID-ERD
J Mullol
TM Laidlaw
Q Dong
C Fan
D Zhang
N Amin
Asif Hameed Khan
J Chao
L Mannent
C3
Conference
2018
Dupilumab in patients with corticosteroid-dependent severe asthma : efficacy and safety results from the randomized, double-blind, placebo-controlled phase 3 LIBERTY ASTHMA VENTURE study
KF Rabe
PK Nair
Guy Brusselle
JF Maspero
M Castro
H Zhu
H Staudinger
G Pirozzi
C Antoni
N. Amin
et al.
C3
Conference
2018
Dupilumab produces rapid and sustained improvements in asthma-related symptoms in patients with uncontrolled, moderate-to-severe asthma from the LIBERTY ASTHMA QUEST study
J Corren
M Castro
S Guillonneau
J Chao
N Amin
G Pirozzi
NMH Graham
A Teper
Asif Hameed Khan
C3
Conference
2018
Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma
Klaus F Rabe
Parameswaran Nair
Guy Brusselle
Jorge F Maspero
Mario Castro
Lawrence Sher
Hongjie Zhu
Jennifer D Hamilton
Brian N Swanson
Asif Hameed Khan
et al.
A1
Journal Article
in
NEW ENGLAND JOURNAL OF MEDICINE
2018
Impact of chronic rhinosinusitis with nasal polyposis on quality of life by sino-nasal surgery history
Asif Hameed Khan
T Huynh
S Kamat
L Mannent
Peter Tomassen
Thibaut Van Zele
Lars-Olaf Cardell
J Arebro
H Olze
U Foerster-Ruhrmann
et al.
C3
Conference
2018
2017
Dupilumab improves all ACQ-5 individual items in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and asthma : results from a phase 2a trial
Peter Hellings
Claus Bachert
Joaquim Mullol
Daniel Hamilos
Robert Naclerio
Vijay Joish
Leda Mannent
Nikhil Amin
Adeline Abbe
Christine Taniou
et al.
C3
Conference
2017
Dupilumab improves sense of smell and reduces anosmia among patients with nasal polyposis and chronic sinusitis : results from a phase 2a trial
Robert M. Naclerio
Daniel L. Hamilos
Berrylin J. Ferguson
Claus Bachert
Peter W. Hellings
Joaquim Mullol
Philippe Gevaert
Donghui Zhang
Asif Hameed Khan
Chunpeng Fan
et al.
C3
Conference
2017
Impact of exacerbations on lung function in patients with asthma
Juan P Wisnivesky
Emily Goodman
Erin West
Nikhil Amin
Vijay Joish
Sara Villeneuve
Laurent Eckert
Ariel Teper
Asif Hameed Khan
C3
Conference
2017
2016
Dupilumab improves health-related quality of life and absenteeism in nasal polyposis patients : results from a phase 2a trial
Claus Bachert
P Hellings
J Mullol
D Hamilos
R Naclerio
VN Joish
L Mannent
R Evans
A Abbe
C. Amand
et al.
C3
Conference
2016
Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma : results from a phase 2a trial
Claus Bachert
Peter Hellings
Joaquim Mullol
Daniel Hamilos
Robert Naclerio
Vijay N Joish
Leda Mannent
Robert E Evans
Annette Grabher
Adeline Abbe
et al.
C3
Conference
2016
2015
The ‘GA^2LEN sinusitis cohort’ : an introduction
Griet Vandeplas
Asif Hameed Khan
Thi Minh Thao Huynh
Peter Tomassen
Thibaut Van Zele
Lars-Olaf Cardell
Julia Arebro
Heidi Olze
Ulrike Foerster
Marek Leszek Kowalski
et al.
C3
Conference
2015